Table 1 Demographic Characteristics of the Participants
From: Safety and immunogenicity of an HIV vaccine trial with DNA prime and replicating vaccinia boost
Groups | Ia | Ib | Total (n = 48) | ||||
|---|---|---|---|---|---|---|---|
rTV-L | rTV-H | DNA-L/ rTV | DNA-H/ rTV | DNA | Placebo | ||
No. of participants | 6 | 6 | 12 | 12 | 6 | 6 | 48 |
Gender—no. (%) | |||||||
Male | 6 (100%) | 5 (83%) | 8 (67%) | 10 (83%) | 4 (67%) | 4 (67%) | 37 (77%) |
Female | 0 (.) | 1 (17%) | 4 (33%) | 2 (17%) | 2 (33%) | 2 (33%) | 11 (23%) |
Ethnic—no. (%) | |||||||
Han | 6 (100%) | 5 (83%) | 12 (100%) | 12 (100%) | 5 (83%) | 6 (100%) | 46 (96%) |
Mongolian | 0 (.) | 1 (17%) | 0 (.) | 0 (.) | 0 (.) | 0 (.) | 1 (2%) |
Manchu | 0 (.) | 0 (.) | 0 (.) | 0 (.) | 1 (16.7%) | 0 (.) | 1 (2%) |
Age—yr | |||||||
Median (range) | 25.2 (20.0–29.0) | 28.7 (23.6–39.2) | 24.8 (19.7–44.7) | 26.6 (22.4–31.4) | 28.5 (23.1–36.6) | 25.9 (21.0–40.6) | 26.3 (19.7–44.7) |
Smallpox vaccination status - no. (%) | |||||||
Naïve | 4 (67%) | 3 (50%) | 7 (58%) | 8 (67%) | 3 (50%) | 5 (83%) | 30 (63%) |
Non-Naive | 2 (33%) | 3 (50%) | 5 (42%) | 4 (33%) | 3 (50%) | 1 (17%) | 18 (38%) |
